An Observational Follow-Up Study for: A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium (Protocol 018)
Latest Information Update: 24 May 2019
At a glance
- Drugs Odanacatib (Primary)
- Indications Osteoporosis
- Focus Adverse reactions; Registrational
- Sponsors Merck Sharp & Dohme
- 31 Oct 2015 Status changed from recruiting to completed as per European Clinical Trials Database record.
- 01 Oct 2013 New trial record